GlaxoSmithKline Plc’s much-maligned diabetes drug Avandia will be released from restrictions preventing sales to certain patients after U.S. regulators determined new data show the medicine doesn’t raise heart risks.
The perceived heart risks that torpedoed sales of GlaxoSmithKline Plc’s best-selling diabetes pill Avandia may have been overstated and restrictions on prescribing the drug should be eased, U.S. advisers said.
Micromet Inc. , a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals.
GlaxoSmithKline Plc. and Merck & Co. and Ariad Pharmaceuticals Inc.’s drugs for a rare, often deadly form of cancer may not offer enough benefits to be worth risks including heart and kidney ailments, U.S. regulators said.
Imagine a prostate cancer therapy that has almost no side effects. Hospitals say it exists and they’re vying to be among the first to offer it. Too bad the treatment may not work as well as advertised and could boost America’s already spiraling health-care costs.
Pfizer Inc. , Johnson & Johnson and a half dozen competitors are committed to a research strategy for Alzheimer’s disease that has resulted in a string of study failures, the most recent involving Eli Lilly & Co.